20 tracked 13F filers disclose a position in APRE as of the latest SEC 13F filings, a combined $937K in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Vestal Point Capital, LP | $267K | 350K | ▲New +350K sh | Q1 2026 | |
| 2 | SPHERA FUNDS MANAGEMENT LTD. | $206K | 270K | —Held | Q1 2026 | |
| 3 | Nantahala Capital Management, LLC | $157K | 206K | —Held | Q1 2026 | |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | $91K | 119K | ▲+191% Added · +78K sh | Q1 2026 | |
| 5 | Scientech Research LLC | $46K | 60K | ▲New +60K sh | Q1 2026 | |
| 6 | BNP PARIBAS FINANCIAL MARKETS | $30K | 40K | ▲+46% Added · +12K sh | Q1 2026 | |
| 7 | VANGUARD FIDUCIARY TRUST CO | $29K | 38K | →First observed position No prior filed position | Q1 2026 | |
| 8 | RENAISSANCE TECHNOLOGIES LLC | $19K | 25K | ▲New +25K sh | Q1 2026 | |
| 9 | MORGAN STANLEY | $17K | 22K | ▼−71% Reduced · −55K sh | Q1 2026 | |
| 10 | LPL Financial LLC | $16K | 21K | ▼−19% Reduced · −5K sh | Q1 2026 | |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | $15K | 20K | →First observed position No prior filed position | Q1 2026 | |
| 12 | HighTower Advisors, LLC | $11K | 14K | —Held | Q1 2026 | |
| 13 | TWO SIGMA SECURITIES, LLC | $10K | 14K | ▲New +14K sh | Q1 2026 | |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | $10K | 13K | ▲New +13K sh | Q1 2026 | |
| 15 | BlackRock, Inc. | $6K | 9K | —Held | Q1 2026 | |
| 16 | Tower Research Capital LLC (TRC) | $4K | 5K | ▼−34% Reduced · −3K sh | Q1 2026 | |
| 17 | UBS Group AG | $2K | 2K | ▼−13% Reduced · −308 sh | Q1 2026 | |
| 18 | GROUP ONE TRADING LLC | $440 | 577 | —Held | Q1 2026 | |
| 19 | OSAIC HOLDINGS, INC. | $225 | 295 | ▼−1.7% Reduced · −5 sh | Q1 2026 | |
| 20 | SBI Securities Co., Ltd. | $12 | 16 | ▲+6.7% Added · +1 sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 4 funds opened a new position in APRE and 1 added to an existing one, while 1 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX | 6 funds | $97.0M |
| LEXEO THERAPEUTICS INCLXEO | 6 funds | $54.9M |
| GERON CORPGERN | 6 funds | $53.2M |
| FULCRUM THERAPEUTICS INCFULC | 6 funds | $42.3M |
| GILEAD SCIENCES INCGILD | 5 funds | $559.0M |
| BIOMARIN PHARMACEUTICAL INCBMRN | 5 funds | $457.6M |
| BOSTON SCIENTIFIC CORPBSX | 5 funds | $321.3M |
| REVOLUTION MEDICINES INCRVMD | 5 funds | $274.7M |
| UNITED THERAPEUTICS CORPUTHR | 5 funds | $258.6M |
| ABBOTT LABORATORIESABT | 5 funds | $198.1M |
| NEUROCRINE BIOSCIENCES INCNBIX | 5 funds | $172.5M |
| DEXCOM INCDXCM | 5 funds | $131.5M |
Ranked by how many of APRE's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jan 30, 2026 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy (P) | 6K | $5K |
| Jan 30, 2026 | Gilad Oren | President/CEO, Director | Buy (P) | 28K | $25K |
| Dec 10, 2025 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy (P) | 5K | $6K |
| Dec 10, 2025 | Duey Marc | Director | Buy (P) | 21K | $25K |
| Apr 3, 2025 | Gilad Oren | President/CEO, Director | Buy (P) | 2K | $4K |
| Apr 3, 2025 | Gilad Oren | President/CEO, Director | Buy (P) | 3K | $6K |
| Oct 23, 2024 | Gilad Oren | President/CEO, Director | Buy (P) | 500 | $2K |
| Oct 18, 2024 | Duey Marc | Director | Sell (S) | 6K | $30K |
| Oct 16, 2024 | Duey Marc | Director | Buy (P) | 30K | $132K |
| Oct 15, 2024 | Gilad Oren | President/CEO, Director | Buy (P) | 250 | $725 |
| Oct 14, 2024 | Gilad Oren | President/CEO, Director | Buy (P) | 1K | $3K |
| Oct 14, 2024 | Duey Marc | Director | Buy (P) | 190 | $490 |
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/APRE/capital-change-brief"
Use Arkolith's capital_change_brief for APRE. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for APRE. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.